Stocklytics Platform
Asset logo for symbol RPTX
Repare Therapeutics
RPTX51
$3.79arrow_drop_up4.46%$0.16
Penny Stock
Asset logo for symbol RPTX
RPTX51

$3.79

arrow_drop_up4.46%

Income Statement (RPTX)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
EBIT-$37.05M$10.81M-$30.45M-$39.42M-$12.21M
EBITDA-$36.57M$11.31M-$29.94M-$38.37M-$11.71M
gross Profit$585.00K$51.90M$12.54M$1.11M$29.19M
NET Income-$34.77M$13.16M-$28.03M-$18.87M-$11.94M
total Revenue$1.07M$52.40M$13.04M$2.15M$30.24M

Balance Sheet (RPTX)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
cash Equivalents-----
net Debt-$77.64M-$100.43M-$107.85M-$103.44M-$110.99M
stockholders Equity$203.67M$231.95M$212.08M$233.36M$245.41M
total Assets$235.34M$263.08M$253.90M$286.40M$301.58M
total Debt$2.17M$2.77M$3.41M$3.92M$4.54M
total Liabilities$31.66M$31.13M$41.81M$53.03M$56.17M

Cash Flow (RPTX)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
financing Cash Flow$0.00$375.00K$105.00K$284.00K$40.00K
free Cash Flow-$30.51M$11.93M-$28.55M-$32.87M-$35.41M
investing Cash Flow---$24.49M$28.35M
operating Cash Flow-$30.51M$11.93M-$28.15M-$32.87M-$34.34M

Repare Therapeutics (RPTX) Financials

Repare Therapeutics Inc (RPTX) is a biotechnology company that focuses on developing novel precision oncology therapeutics. The company's financial performance is reflected in its income statement. The income statement provides an overview of the company's revenues, expenses, and net income from stockholders over a specific period. It includes the total revenue generated by Repare Therapeutics Inc, which represents the sum of all the company's sources of income. The gross profit is the revenue minus the cost of goods sold. It represents the amount of money the company has left after accounting for the direct production costs.
The earnings before interest and taxes (EBIT) is a measure of Repare Therapeutics Inc's operating profitability. It shows how much profit the company generates from its operations before taking into account interest expenses and income taxes. EBITDA, which stands for earnings before interest, taxes, depreciation, and amortization, is another financial metric used to assess Repare Therapeutics Inc's profitability. It provides a clearer picture of the company's operating performance by excluding non-cash expenses and the effects of financing activities.
The balance sheet is a snapshot of Repare Therapeutics Inc's financial condition at a specific point in time. It provides information about the company's assets, liabilities, and stockholders' equity. The total assets represent all the resources owned by the company, including cash equivalents and properties. The total liabilities include the company's debts and other obligations. The net debt is calculated by subtracting the cash equivalents from the total debt. The stockholders' equity is the residual interest in the assets of Repare Therapeutics Inc after deducting liabilities.
In terms of cash flow, Repare Therapeutics Inc's cash flow statement provides insights into how the company generates and uses its cash. The operating cash flow represents the cash generated or used by the company's core operations. The investing cash flow shows the cash flows related to investing activities, such as capital expenditures or acquisitions. The financing cash flow reflects the cash flows from financing activities, including any borrowings or repayments. Free cash flow is the amount of cash available for distribution to investors after deducting capital expenditures.
In conclusion, Repare Therapeutics Inc's financials provide a comprehensive view of the company's performance and financial position. The income statement, EBIT, EBITDA, gross profit, and net income from stockholders reflect the company's profitability. The balance sheet reveals the company's assets, liabilities, and stockholders' equity, while the cash flow statement shows how Repare Therapeutics Inc generates and uses its cash.
add Repare Therapeutics  to watchlist

Keep an eye on Repare Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level